Folic Acid

Introduction Overview

Generic Name

folic acid

Brand Name

FA-8
Folacin-800
FaLessa
Folvite

Dosage Form

oral tablet (0.4 mg; 0.8 mg; 1 mg), injection

Drug Class

Vitamins

Pharmacokinetics

Absorption:
Folic acid, the synthetic form of vitamin B9, is efficiently absorbed primarily in the proximal small intestine, including the duodenum and jejunum. It shows higher bioavailability than natural food folates due to its stability and resistance to degradation in the gastrointestinal tract. Oral folic acid is rapidly absorbed, with peak plasma concentrations typically occurring within 1 to 2 hours post-dose. Factors such as gastrointestinal malabsorption syndromes (e.g., celiac disease or inflammatory bowel disease) can impair folic acid absorption, necessitating higher or parenteral doses in affected patients. The drug can also be absorbed via parenteral routes (intramuscular, subcutaneous, or intravenous injections) when oral administration is not feasible or effective.

Distribution:
Once absorbed, folic acid is distributed widely throughout the body, with significant uptake by the liver, where it is converted to its active form tetrahydrofolate and polyglutamate derivatives. The liver serves as a critical storage and metabolic site. Folate cofactors are then distributed to peripheral tissues including the bone marrow (important for erythropoiesis), placenta, and fetal tissues during pregnancy. The volume of distribution is extensive because folate is intracellularly bound and actively transported within cells. Folate readily crosses the placenta to support fetal development and is also excreted in breast milk. Protein binding is minimal, facilitating widespread tissue exposure.

Metabolism:
Folic acid undergoes an initial reduction and methylation in the liver to form 5-methyltetrahydrofolate, the biologically active circulating form. This active metabolite participates in one-carbon transfer reactions critical for DNA synthesis, repair, and methylation processes. The conversion to active forms allows folate to participate in the regeneration of methionine from homocysteine, a key biochemical pathway implicated in cellular methylation and cardiovascular risk modulation. Metabolic activity also involves polyglutamation within cells, which helps retain folate in tissues. Genetic polymorphisms, such as MTHFR C677T, can affect folate metabolism and utilization efficiency.

Elimination:
Folic acid and its metabolites are primarily eliminated via the kidneys through renal excretion. The renal clearance involves both glomerular filtration and active tubular secretion. Urinary excretion increases in cases of folate oversupplementation, and unmetabolized folic acid can be detected in plasma and urine with high oral doses. Small amounts are also lost via bile and feces. The elimination half-life varies depending on tissue stores, folate status, and renal function, but typically ranges from several hours to days. Impaired renal function can lead to accumulation, requiring dose adjustments. The body maintains a folate pool that buffers short-term fluctuations in intake.

Dosage Forms

Available Dosage Forms:
Folic acid is available primarily as oral tablets and injectable solutions. Oral tablets come in strengths of 0.4 mg, 0.8 mg, and 1 mg, commonly used for dietary supplementation and treatment of deficiency states. Injectable preparations are available for intramuscular, subcutaneous, or intravenous administration, reserved for patients who cannot absorb folic acid orally, such as those receiving parenteral nutrition or with severe malabsorption.

Dosages for Adults and Adolescents:
Standard dosing for adults to prevent folate deficiency is 0.4 mg (400 mcg) daily, matching the recommended dietary allowance (RDA). For pregnant women, the RDA increases to 600 mcg daily to reduce the risk of neural tube defects. For treatment of folate-deficiency anemia, adults typically receive 1 mg of folic acid orally once daily, with doses up to 5 mg per day in refractory cases or where higher requirements exist. Adolescents generally follow adult dosing guidelines but adjusted according to age and clinical condition.

Specific Patient Populations:
Pregnant Women: Recommended to begin folic acid 400 mcg daily before conception and continue through early pregnancy to prevent neural tube defects. Higher doses (up to 5 mg) may be used for women at high risk or with previous affected pregnancies.
Breastfeeding Mothers: Require about 500 mcg daily, with supplementation considered if maternal deficiency is present or in low-birthweight infants.
Patients on Methotrexate Therapy: 5 mg weekly folic acid supplementation on a different day from methotrexate to reduce toxicity.
Patients with Malabsorption or Inability to Take Oral Medications: May require folic acid injections to ensure adequate status.

Summary of Dosage Forms:
- Oral tablet: 0.4 mg, 0.8 mg, 1 mg
- Injection: parenteral preparations suitable for intramuscular, subcutaneous, or intravenous administration

Mechanism Of Action

Folic acid acts as a vital precursor in the metabolic pathway of folate-dependent one-carbon transfers essential for nucleotide biosynthesis. Once absorbed, folic acid is enzymatically reduced to dihydrofolate and then to tetrahydrofolate (THF), which serves as a carrier of one-carbon units through multiple folate coenzymes. These activated folate derivatives participate in the synthesis of purines and thymidylate, critical components of DNA and RNA.

At the cellular level, folate cofactors facilitate the conversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate (dTMP) by donating a methyl group, a reaction catalyzed by thymidylate synthase. This step is indispensable for DNA replication and repair, particularly in rapidly dividing cells such as hematopoietic precursors. Additionally, folate is required for the remethylation of homocysteine to methionine, mediated by methionine synthase, a vitamin B12-dependent enzyme. This process is crucial for methylation reactions that regulate gene expression and maintain cellular function.

Clinically, folic acid supplementation prevents megaloblastic anemia by restoring the synthesis of purines and thymidylate, allowing for normal erythrocyte maturation and proliferation. Furthermore, folic acid's role in one-carbon metabolism supports fetal neural tube closure during early embryogenesis, implicating its preventive role in neural tube defects. Comparative to other antifolate agents like methotrexate, which inhibit dihydrofolate reductase, folic acid supplementation can mitigate toxicity by replenishing folate pools, thereby balancing necessary cellular functions while chemotherapy or immunosuppressant treatment proceeds.

Research evidence supports folic acid's benefits in lowering serum homocysteine levels, a cardiovascular risk factor, by enhancing remethylation pathways. Additionally, emerging data suggest folic acid may influence neurological functions including mood regulation and cognitive performance through methylation control. These multifaceted biochemical actions underpin folic acid's broad therapeutic utility in hematology, obstetrics, and preventive medicine.

Pharmacological Actions

Prevention and treatment of folate-deficiency anemia by restoring normal erythropoiesis.
Reduction of elevated homocysteine levels through enhanced remethylation to methionine, thereby lowering cardiovascular risk.
Prevention of neural tube defects and other congenital malformations during fetal development.
Adjunctive therapy to reduce methotrexate-induced folate deficiency toxicity.
Support of DNA synthesis, repair, and methylation in rapidly proliferating cells.
Facilitation of one-carbon transfer reactions integral to amino acid metabolism and nucleic acid production.
Mitigation of side effects related to folate deficiency, including neurological and hematologic symptoms.
Potential neuroprotective and mood-regulating effects through methylation pathway modulation.
Contribution to normal cellular growth, differentiation, and tissue repair.
Modulation of immune function through support of nucleotide synthesis in lymphocytes.
Enhancement of maternal and fetal health by supporting optimal nutrient status during pregnancy.
Possible cancer risk reduction via optimization of DNA synthesis and repair mechanisms.
Support of infant nutrition during breastfeeding by transfer in human milk.
Counteraction of drug-induced folate depletion caused by antiepileptic and antimicrobial agents.
Maintenance of normal gene expression patterns through regulation of methylation.

Therapeutic Or Clinical Uses

Prevention and treatment of folate-deficiency (megaloblastic) anemia.
Prevention of neural tube defects such as spina bifida and anencephaly in developing fetuses.
Reduction of hyperhomocysteinemia to decrease cardiovascular disease risk.
Supplementation in patients receiving methotrexate therapy to reduce associated toxicity.
Management of folate deficiency due to malabsorption, poor dietary intake, or increased demand.
Support during pregnancy and lactation to meet increased folate requirements.
Treatment of certain congenital malformations linked to folate deficiency (congenital heart defects, cleft lip/palate).
Adjunct therapy in anemia where vitamin B12 deficiency has been ruled out.
Support of cognitive function and mood disorders, including depression adjunct treatment.
Potential use in reducing risk or progression of dementia and autism spectrum disorders (investigational).
Correction of folate deficits in alcohol use disorder and other chronic illnesses.
Use in pediatric populations to ensure adequate growth and development.
Part of multivitamin and mineral supplementation regimens for general health support.
Prevention of folate depletion during use of folate-antagonist drugs like anticonvulsants and sulfasalazine.
Use in parenteral nutrition formulations to maintain folate levels when oral intake is compromised.

Side Or Adverse Effects

Nausea and gastrointestinal discomfort including bloating and stomach pain.
Loss of appetite and occasional bitter or unpleasant taste in the mouth.
Mild neurological symptoms such as confusion, trouble concentrating, and mood changes.
Sleep disturbances including insomnia or altered sleep patterns.
Rare allergic reactions manifesting as rash, hives, itching, or skin redness.
Potential exacerbation of seizures in patients with epilepsy on anticonvulsant therapy.
Possible masking of vitamin B12 deficiency leading to progressive neurological damage if untreated.
Headache or irritability in some individuals.
Gastrointestinal symptoms such as gas or abdominal discomfort at higher doses.
Mild swelling or redness at injection site with parenteral administration.
Rare cases of hypersensitivity reactions leading to respiratory distress or anaphylaxis.
Confusion and impaired judgment reported occasionally with high-dose supplementation.
Mood disturbances including depression or excitement.
No significant toxicity reported with standard dosing; high doses require caution.
Possible low serum B12 levels with prolonged folic acid therapy, necessitating monitoring.

Precautions

Do not use if there is a known allergy to folic acid or its components.
Use cautiously in patients with undiagnosed anemia until vitamin B12 deficiency is excluded.
Monitor closely in patients with seizure disorders as folic acid may lower seizure threshold.
Adjust dosage or consider alternative routes in patients with malabsorption syndromes.
Avoid excessive folic acid intake in pregnancy without medical supervision to prevent masking B12 deficiency.
Use with caution in patients with liver or kidney disease; dose adjustments may be necessary.
Supplementation should not replace appropriate treatment for underlying causes of anemia.
Patients on high-dose folic acid should be monitored for neurological signs suggestive of B12 deficiency.
Caution in patients receiving anticonvulsant therapy due to potential attenuation of drug efficacy.
Regular hematological and metabolic monitoring recommended during long-term therapy.
Assess dietary intake prior to supplementation to avoid unnecessary folic acid administration.
Consider genetic factors (e.g., MTHFR mutations) that may influence folate metabolism and requirements.
Ensure dose is appropriate during pregnancy and lactation to meet increased physiological demands.
Beware of potential interactions with other folate antagonists or supplements.
Use under medical supervision when combined with other vitamin or mineral therapies.

Warnings

May mask the hematological symptoms of vitamin B12 deficiency, allowing neurological damage to progress if untreated.
Potential to increase seizure frequency in patients with epilepsy receiving phenobarbital, primidone, or phenytoin.
Serious allergic reactions, although rare, require immediate emergency medical attention.
Avoid high doses without medical supervision, especially in pregnancy, to reduce risk of adverse outcomes.
Do not exceed recommended doses without consulting a healthcare provider to prevent toxicity.
Use caution in patients with underlying hematologic or neurologic disorders without confirmatory diagnosis.
Patients with alcohol use disorder may require higher dose supplementation due to increased needs.
Folic acid supplementation should not be used to self-treat symptoms indicative of pernicious anemia.
Monitor for signs of folate deficiency despite supplementation in patients with malabsorption or drug interactions.
Use parenteral folic acid only when oral administration is insufficient or contraindicated.
Discontinue and seek medical help if signs of allergic reaction occur during therapy.
Careful diagnostic evaluation is necessary to rule out B12 deficiency prior to folic acid administration.
Avoid folic acid supplementation to enhance fertility without definitive evidence or medical advice.
Pregnant women should initiate supplementation prior to conception to maximize benefits.
Be aware that folic acid may alter laboratory assays related to folate and antimicrobial therapy.

Contraindication

Known hypersensitivity or allergic reaction to folic acid or any component of the formulation.
Untreated pernicious anemia without concurrent vitamin B12 therapy due to risk of masking deficiency.
Patients with hemolytic anemia unless under careful medical supervision and confirmed diagnosis.
Severe allergy to folic acid injection excipients in injectable formulations.
Patients who have experienced anaphylactic reactions to folic acid should avoid re-exposure.
Individuals with undiagnosed anemia without appropriate laboratory workup should not be treated solely with folic acid.
Contraindicated as sole therapy in megaloblastic anemia due to vitamin B12 deficiency.
Patients with known allergy to same-class vitamins should be evaluated cautiously.
Use in epilepsy patients necessitates caution, but not strictly contraindicated unless hypersensitivity present.
Injections contraindicated in patients with hypersensitivity to parenteral vitamins or preservatives.
Patients with iron overload disorders require careful monitoring and are not contraindicated per se but need specialist input.
Should not replace comprehensive therapy for nutritional deficiencies without medical oversight.
Contraindicated for unsupervised use in populations at risk for B12 deficiency neurological complications.
Avoid administration in individuals with documented sensitivity to folate-related compounds.
Contraindicated in absence of clinical indication or for non-nutritional use.

Drug Interactions

Methotrexate: Folic acid supplementation reduces methotrexate toxicity but may interfere with its efficacy, requiring careful dosing and timing.
Phenytoin and Primidone: Folic acid may antagonize the anticonvulsant effect, potentially necessitating higher doses of these medications.
Phenobarbital and Secobarbital: These barbiturates may increase folate metabolism leading to decreased levels; folic acid may also reduce their efficacy.
Sulfasalazine: May inhibit intestinal folate absorption, reducing folate bioavailability.
Pyrimethamine: An antifolate that competes with folic acid, decreasing its effectiveness.
Nitrofurantoin: May interfere with folate metabolism and utilization.
Certain antibiotics (e.g., tetracycline) that suppress intestinal flora may falsely lower measured serum or red blood cell folate levels.
Anticonvulsants may increase folate requirements and alter pharmacokinetics of folic acid.
Drugs that impair absorption or increase folate excretion may reduce folic acid effectiveness.
Folic acid supplementation can alter laboratory test results, including folate assays and homocysteine levels.
Interactions with other B vitamins may modify folic acid metabolism.
Concurrent use with levodopa may theoretically reduce efficacy of levodopa, although clinical significance is uncertain.
High-dose folic acid may interfere with certain chemotherapeutic agents.
Supplementation may affect efficacy of drugs metabolized through methylation pathways.
Drugs causing malabsorption or increasing folate loss require monitoring and dose adjustments.

Preparations Of The Drug

Oral tablets available in strengths of 0.4 mg, 0.8 mg, and 1 mg.
Parenteral formulations suitable for intramuscular, subcutaneous, or intravenous injection.
Combination multivitamin supplements including folic acid and other B-complex vitamins.
Prenatal vitamins containing folic acid in doses ranging from 400 mcg to 800 mcg.
Folic acid supplements available as single-ingredient products and in combo preparations with iron or other minerals.
Extended-release formulations are typically not necessary due to efficient absorption and utilization.
Over-the-counter availability in variable dose strengths to support dietary supplementation.
Prescription formulations for higher-dose therapeutic use in deficiency states.
Methylfolate (L-methylfolate) products as active folate derivatives for specific genetic or metabolic needs.
Injectable folic acid preparations for patients requiring parenteral nutrition or with severe malabsorption.
Available as capsules, tablets, and parenteral vials depending on formulation and manufacturer.
Typically supplied in blister packs, bottles, or injection vials with appropriate labeling for dosing and storage.
Folic acid tablets may be film-coated or uncoated; film coatings enhance swallowing and taste masking.
Some oral preparations may be part of fortified foods and cereal grain products under regulatory mandates.
Supplements often combined with other vitamins or minerals for comprehensive nutritional support.